CD4/CD8 ratio predicts yellow fever vaccine-induced antibody titers in virologically suppressed HIV-infected patients

dc.creatorAvelino-Silva, Vivian
dc.creatorMiyaj, Karina Takesaki
dc.creatorMathias, Augusto
dc.creatorCosta, Dayane Alves
dc.creatorDias, Juliana Zanatta de Carvalho
dc.creatorLima, Sheila Barbosa
dc.creatorSimoes, Marisol
dc.creatorFreire, Marcos S.
dc.creatorCaiaffa-Filho, Helio H.
dc.creatorHong, Marisa A.
dc.creatorLopes, Marta H.
dc.creatorSartori, Ana M.
dc.creatorKallas, Esper Georges
dc.date2019-03-20T19:34:21Z
dc.date2019-03-20T19:34:21Z
dc.date2016
dc.date.accessioned2023-09-26T23:57:10Z
dc.date.available2023-09-26T23:57:10Z
dc.identifierAVELINO-SILVA, Vivian Iida et al. CD4/CD8 Ratio Predicts Yellow Fever Vaccine-Induced Antibody Titers in Virologically Suppressed HIV-Infected Patients. Journal Of Acquired Immune Deficiency Syndromes, Hagerstown, v. 71, n. 2, p.189-195, 2016.
dc.identifier1944-7884
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/32186
dc.identifier10.1097/QAI.0000000000000845
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8895939
dc.descriptionBACKGROUND: Yellow fever vaccine (YFV) induces weaker immune responses in HIV-infected individuals. However, little is known about YFV responses among antiretroviral-treated patients and potential immunological predictors of YFV response in this population. METHODS: We enrolled 34 antiretroviral therapy (ART)-treated HIV-infected and 58 HIV-uninfected adults who received a single YFV dose to evaluate antibody levels and predictors of immunity, focusing on CD4(+) T-cell count, CD4(+)/CD8(+) ratio, and Human Pegivirus (GBV-C) viremia. Participants with other immunosuppressive conditions were excluded. RESULTS: Median time since YFV was nonsignificantly shorter in HIV-infected participants than in HIV-uninfected participants (42 and 69 months, respectively, P = 0.16). Mean neutralizing antibody (NAb) titers was lower in HIV-infected participants than HIV-uninfected participants (3.3 vs. 3.6 log10mIU/mL, P = 0.044), a difference that remained significant after adjustment for age, sex, and time since vaccination (P = 0.024). In HIV-infected participants, lower NAb titers were associated with longer time since YFV (rho: -0.38, P = 0.027) and lower CD4(+)/CD8(+) ratio (rho: 0.42, P = 0.014), but not CD4(+) T-cell count (P = 0.52). None of these factors were associated with NAb titers in HIV-uninfected participant. GBV-C viremia was not associated with difference in NAb titers overall or among HIV-infected participants. CONCLUSIONS: ART-treated HIV-infected individuals seem to have impaired and/or less durable responses to YFV than HIV-uninfected individuals, which were associated with lower CD4(+)/CD8(+) ratio, but not with CD4(+) T-cell count. These results supports the notion that low CD4(+)/CD8(+) ratio, a marker linked to persistent immune activation, is a better indicator of functional immune disturbance than CD4(+) T-cell count in patients with successful ART.
dc.formatapplication/pdf
dc.languageeng
dc.rightsopen access
dc.subjectYellow fever vaccine
dc.subjectYellow fever neutralizing antibodies
dc.subjectHIV
dc.subjectCD4+/CD8+ ratio
dc.subjectImmune activation
dc.titleCD4/CD8 ratio predicts yellow fever vaccine-induced antibody titers in virologically suppressed HIV-infected patients
dc.typeArticle


Este ítem pertenece a la siguiente institución